# A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

> **NCT05941442** · PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 80 (actual)

## Conditions studied

- Panic Disorder

## Interventions

- **DRUG:** Darigabat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05941442
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-07-31
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 80 (ACTUAL)
- **Why stopped:** Sponsor terminated due to significant enrollment and study design challenges
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05941442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05941442, "A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05941442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*